We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cambridge, MA-based Biogen Inc. (BIIB - Free Report) one of the world’s leading biotechnology companies, focuses on therapeutic areas including neurology and immunology. The company is best known for its multiple sclerosis (MS) franchise comprising treatments like Avonex, Tysabri, Tecfidera and Plegridy.
Meanwhile, in Feb 2017, the company spinned-off its hemophilia business which allows it to focus on neurology, its key area of expertise.
BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 6.41%.
Currently, Biogen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Biogen’s third quarter 2017 earnings were better-than expected. The company posted earnings of $6.31 per share while our consensus called for EPS of $5.70.
Revenues Beat: Biogen posted revenues of $3.09 billion, beating the consensus estimate of $3.04 billion. Revenue increased 4% year over year and 13% excluding hemophilia revenues.
Key Statistics: Oral multiple sclerosis (MS) drug Tecfidera’s revenues increased 3% year over year but decreased 4% sequentially. The other MS drug, Tysabri’s sales decreased 5% sequentially.
Pre-Market Trading: Shares were up more than 1% in pre-market trading.
Check back later for our full write up on this BIIB earnings report later!
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Biogen (BIIB) Beats on Q3 Earnings and Revenue
Cambridge, MA-based Biogen Inc. (BIIB - Free Report) one of the world’s leading biotechnology companies, focuses on therapeutic areas including neurology and immunology. The company is best known for its multiple sclerosis (MS) franchise comprising treatments like Avonex, Tysabri, Tecfidera and Plegridy.
Meanwhile, in Feb 2017, the company spinned-off its hemophilia business which allows it to focus on neurology, its key area of expertise.
BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 6.41%.
Biogen Inc. Price and EPS Surprise
Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote
Currently, Biogen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Biogen’s third quarter 2017 earnings were better-than expected. The company posted earnings of $6.31 per share while our consensus called for EPS of $5.70.
Revenues Beat: Biogen posted revenues of $3.09 billion, beating the consensus estimate of $3.04 billion. Revenue increased 4% year over year and 13% excluding hemophilia revenues.
Key Statistics: Oral multiple sclerosis (MS) drug Tecfidera’s revenues increased 3% year over year but decreased 4% sequentially. The other MS drug, Tysabri’s sales decreased 5% sequentially.
Pre-Market Trading: Shares were up more than 1% in pre-market trading.
Check back later for our full write up on this BIIB earnings report later!
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>